氯吡格雷对冠心病患者PCI前后CD40配体的影响  

Effect of clopidogrel on platelet membrane and serum CD40 ligand in coronary artery disease patients undertaking percutaneous coronary intervention

作　　者：张新霞[1] 段雯[1] 魏文斌[1] 张允奇[1] 许香广[1] 胡雪松[1] 

机构地区：[1]广东医学院附属福田医院心内科,广东深圳518033

出　　处：《心血管康复医学杂志》2009年第5期467-469,共3页Chinese Journal of Cardiovascular Rehabilitation Medicine

基　　金：深圳市科技计划项目(JH200507120939H)

摘　　要：目的:探讨冠心病患者血小板膜CD40配体(CD40L)和血清可溶性CD40配体(sCD40L)在冠脉内介入治疗(PCI)前后的变化及其临床意义。方法:选择30例经冠状动脉造影确诊为冠心病的患者,接受规范的抗心绞痛治疗,术前给予氯吡格雷75mg/d,行PCI术前及术后6h,采用流式细胞仪测定患者活化血小板CD40L的表达率,采用酶联免疫吸附法测定血清sCD40L的含量。结果:30例冠心病患者PCI术前血小板CD40L的表达率水平为(3.73±2.15)%,术后6h为(2.46±0.90)%,较术前显著降低(P<0.01)。PCI术前血清sCD40L的含量为(11.72±4.25)ng/ml,术后6h为(9.98±3.32)ng/ml,较术前显著降低(P<0.01)。结论:氯吡格雷降可低冠心病患者PCI术后早期血清和血小板膜CD40L的含量和表达,预防血栓栓塞事件发生。Objective： To investigate the change and clinical significance of clopidogrel on piatelet membrane and serum CD40L in coronary artery disease patients before and after percutaneous coronary intervention （PCI）. Methods： The 30 cases who were diagnosis coronary artery diseases （CAD） by coronary angiography. All the patients treated with PCI. Before PCI, all the patients took clopidogrel 75rag per day. Activated platelet membrane CD40L express rate was measured by Flow cytometry before and after PCI 6 h, Serum soluble CD40L concentration was measured by enzyme linked immunosorbent assay （ELISA）. Results： Activated platelet membrane CD40L express rate was （3.73±2.15） % and （2.46 ±0. 90）% respectively before and after PCI 6 h （P〈0.01） in 30 patients. Serum soluble CD40L concentrations was （11. 72±4.25） ng/ml and （9.98±3.32） ng/ml respectively before and after PCI 6 h in 30 patients （P〈0.01）. Conclusion： Clopidogrel can decrease platelet activation and prevent thromboembolism event occurrence.

关 键 词：血小板 CD40配体 氯吡格雷 血管成形术 经腔 经皮冠状动脉 

分 类 号：R541.4[医药卫生—心血管疾病]